A Study of DS-2248 in Participants With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2014-02-13
Target enrollment:
Participant gender:
Summary
This phase 1 clinical trial is intended to understand the safety and tolerability of a new
anticancer drug in subjects with advanced solid tumors. The patients who qualify for the
study will receive a once daily dose of the drug taken by mouth and will undergo several
tests to measure the drug in the blood and to understand the safety, tolerability and any
effect of the drug on the tumor. The antitumor effect of the drug is not known in human.